This article was originally published in SRA
Lords ruling clarifies the test of novelty
You may also be interested in...
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.
Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.